Abstract
The major goals of translational research in osteosarcoma entail the identification of prognostic factors and therapeutic targets. Given the relevance of epidermal growth factor receptor pathway to breast cancer and the fi nding that HER-2 was expressed in a proportion of osteosarcoma, it was reasonable to investigate this pathway further. Investigations of HER-2 in osteosarcoma have led to the publication of numerous confl icting reports with regard to the level and prognostic value of HER-2 expression, which are reviewed and discussed. Numerous lessons provided by this research experience are described. This pathway has also been explored as a therapeutic target with at least one study of trastuzumab for the treatment of osteosarcoma completed. Other studies utilizing alternative approaches to target the HER-2 receptor for the treatment of osteosarcoma have been considered.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 161-177 |
| Number of pages | 17 |
| Journal | Advances in Experimental Medicine and Biology |
| Volume | 804 |
| DOIs | |
| State | Published - 2014 |
Fingerprint
Keywords
- Human epidermal growth factor receptor (HER-2)
- Immunohistochemistry
- Osteosarcoma
- Targeted therapy
- Trastuzumab
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
- Medicine(all)
Cite this
Her-2 involvement in osteosarcoma. / Gill, Jonathan; Geller, David S.; Gorlick, Richard.
In: Advances in Experimental Medicine and Biology, Vol. 804, 2014, p. 161-177.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Her-2 involvement in osteosarcoma
AU - Gill, Jonathan
AU - Geller, David S.
AU - Gorlick, Richard
PY - 2014
Y1 - 2014
N2 - The major goals of translational research in osteosarcoma entail the identification of prognostic factors and therapeutic targets. Given the relevance of epidermal growth factor receptor pathway to breast cancer and the fi nding that HER-2 was expressed in a proportion of osteosarcoma, it was reasonable to investigate this pathway further. Investigations of HER-2 in osteosarcoma have led to the publication of numerous confl icting reports with regard to the level and prognostic value of HER-2 expression, which are reviewed and discussed. Numerous lessons provided by this research experience are described. This pathway has also been explored as a therapeutic target with at least one study of trastuzumab for the treatment of osteosarcoma completed. Other studies utilizing alternative approaches to target the HER-2 receptor for the treatment of osteosarcoma have been considered.
AB - The major goals of translational research in osteosarcoma entail the identification of prognostic factors and therapeutic targets. Given the relevance of epidermal growth factor receptor pathway to breast cancer and the fi nding that HER-2 was expressed in a proportion of osteosarcoma, it was reasonable to investigate this pathway further. Investigations of HER-2 in osteosarcoma have led to the publication of numerous confl icting reports with regard to the level and prognostic value of HER-2 expression, which are reviewed and discussed. Numerous lessons provided by this research experience are described. This pathway has also been explored as a therapeutic target with at least one study of trastuzumab for the treatment of osteosarcoma completed. Other studies utilizing alternative approaches to target the HER-2 receptor for the treatment of osteosarcoma have been considered.
KW - Human epidermal growth factor receptor (HER-2)
KW - Immunohistochemistry
KW - Osteosarcoma
KW - Targeted therapy
KW - Trastuzumab
UR - http://www.scopus.com/inward/record.url?scp=84907169734&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84907169734&partnerID=8YFLogxK
U2 - 10.1007/978-3-319-04843-7_9
DO - 10.1007/978-3-319-04843-7_9
M3 - Article
C2 - 24924174
AN - SCOPUS:84907169734
VL - 804
SP - 161
EP - 177
JO - Advances in Experimental Medicine and Biology
JF - Advances in Experimental Medicine and Biology
SN - 0065-2598
ER -